Diagnostic impact of cerebrospinal fluid biomarker (pre-)analytical variability in Alzheimer’s disease

Manuscript Number: 

15-0953R1

Author(s): 
Peter Paul De Deyn, Sebastiaan Engelborghs, Johan Goeman, Joery Goossens, Jean-Jacques Martin, Ellis Niemantsverdriet, Hanne Struyfs, Hugo Vanderstichele

Disclosures

Peter Paul De Deyn

  • Consulting Fees:
    Consulting function for Johnson and Johnson, Janssen Research Foundation

Sebastiaan Engelborghs

  • Consulting Fees:
    consulting fees or paid advisory boards: Innogenetics / Fujirebio Europe, Lundbeck, Pfizer, Novartis, UCB, Roche diagnostics, Nutricia / Danone
    Grants
    • Agency: 
      Janssen Pharmaceutica
      Dates: 
      1 SEP 2012

Johan Goeman

  • Nothing to Disclose

Joery Goossens

  • Nothing to Disclose

Jean-Jacques Martin

  • Nothing to Disclose

Ellis Niemantsverdriet

  • Nothing to Disclose

Hanne Struyfs

  • Nothing to Disclose

Hugo Vanderstichele